124 related articles for article (PubMed ID: 38662983)
1. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma.
Su DG; Djureinovic D; Schoenfeld D; Marquez-Nostra B; Olino K; Jilaveanu L; Kluger H
JCO Precis Oncol; 2024 Apr; 8():e2300702. PubMed ID: 38662983
[TBL] [Abstract][Full Text] [Related]
2. Melanocortin 1 receptor (MC1R) expression as a marker of progression in melanoma.
Su D; Djureinovic D; Schoenfeld D; Marquez-Nostra B; Olino K; Jilaveanu L; Kluger H
Res Sq; 2023 Sep; ():. PubMed ID: 37790306
[TBL] [Abstract][Full Text] [Related]
3. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population.
Landi MT; Kanetsky PA; Tsang S; Gold B; Munroe D; Rebbeck T; Swoyer J; Ter-Minassian M; Hedayati M; Grossman L; Goldstein AM; Calista D; Pfeiffer RM
J Natl Cancer Inst; 2005 Jul; 97(13):998-1007. PubMed ID: 15998953
[TBL] [Abstract][Full Text] [Related]
4. Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma.
Vernali S; Waxweiler WT; Dillon PM; Kanetsky PA; Orlow I; Luo L; Busam KJ; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Thomas NE;
JAMA Dermatol; 2017 Oct; 153(10):1026-1031. PubMed ID: 28746718
[TBL] [Abstract][Full Text] [Related]
5. MC1R variants and cutaneous melanoma risk according to histological type, body site, and Breslow thickness: a pooled analysis from the M-SKIP project.
Caini S; Gandini S; Botta F; Tagliabue E; Raimondi S; Nagore E; Zanna I; Maisonneuve P; Newton-Bishop J; Polsky D; Lazovich D; Kumar R; Kanetsky PA; Hoiom V; Ghiorzo P; Landi MT; Ribas G; Menin C; Stratigos AJ; Palmieri G; Guida G; García-Borrón JC; Nan H; Little J; Sera F; Puig S; Fargnoli MC;
Melanoma Res; 2020 Oct; 30(5):500-510. PubMed ID: 32898390
[TBL] [Abstract][Full Text] [Related]
6. Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors.
Guida M; Strippoli S; Ferretta A; Bartolomeo N; Porcelli L; Maida I; Azzariti A; Tommasi S; Grieco C; Guida S; Albano A; Lorusso V; Guida G
Pigment Cell Melanoma Res; 2016 Nov; 29(6):679-687. PubMed ID: 27540956
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.
Li M; Liu D; Lee D; Kapoor S; Gibson-Corley KN; Quinn TP; Sagastume EA; Mott SL; Walsh SA; Acevedo MR; Johnson FL; Schultz MK
Mol Pharm; 2019 Sep; 16(9):3904-3915. PubMed ID: 31318566
[TBL] [Abstract][Full Text] [Related]
8. MC1R genotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study.
Cust AE; Goumas C; Vuong K; Davies JR; Barrett JH; Holland EA; Schmid H; Agha-Hamilton C; Armstrong BK; Kefford RF; Aitken JF; Giles GG; Bishop D; Newton-Bishop JA; Hopper JL; Mann GJ; Jenkins MA
BMC Cancer; 2013 Sep; 13():406. PubMed ID: 24134749
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and histologic characteristics of cutaneous melanoma in patients with melanocortin-1 receptor polymorphisms.
Avilés JA; Lázaro P; Fernández LP; Benítez J; Ibarrola-Villava M; Ribas G
Actas Dermosifiliogr; 2012 Jan; 103(1):44-50. PubMed ID: 22464597
[TBL] [Abstract][Full Text] [Related]
10. [Phenotypic and histologic characteristics of cutaneous melanoma in patients with melanocortin-1 receptor polymorphisms].
Avilés JA; Lázaro P; Fernández LP; Benítez J; Ibarrola-Villava M; Ribas G
Actas Dermosifiliogr; 2012; 103(1):44-50. PubMed ID: 21737053
[TBL] [Abstract][Full Text] [Related]
11. The determinants of periorbital skin ageing in participants of a melanoma case-control study in the U.K.
Suppa M; Elliott F; Mikeljevic JS; Mukasa Y; Chan M; Leake S; Karpavicius B; Haynes S; Bakker E; Peris K; Barrett JH; Bishop DT; Newton Bishop JA
Br J Dermatol; 2011 Nov; 165(5):1011-21. PubMed ID: 21787368
[TBL] [Abstract][Full Text] [Related]
12. Melanocortin 1 receptor (MC1R) polymorphisms' influence on size and dermoscopic features of nevi.
Vallone MG; Tell-Marti G; Potrony M; Rebollo-Morell A; Badenas C; Puig-Butille JA; Gimenez-Xavier P; Carrera C; Malvehy J; Puig S
Pigment Cell Melanoma Res; 2018 Jan; 31(1):39-50. PubMed ID: 28950052
[TBL] [Abstract][Full Text] [Related]
13. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort.
Pellegrini C; Botta F; Massi D; Martorelli C; Facchetti F; Gandini S; Maisonneuve P; Avril MF; Demenais F; Bressac-de Paillerets B; Hoiom V; Cust AE; Anton-Culver H; Gruber SB; Gallagher RP; Marrett L; Zanetti R; Dwyer T; Thomas NE; Begg CB; Berwick M; Puig S; Potrony M; Nagore E; Ghiorzo P; Menin C; Manganoni AM; Rodolfo M; Brugnara S; Passoni E; Sekulovic LK; Baldini F; Guida G; Stratigos A; Ozdemir F; Ayala F; Fernandez-de-Misa R; Quaglino P; Ribas G; Romanini A; Migliano E; Stanganelli I; Kanetsky PA; Pizzichetta MA; García-Borrón JC; Nan H; Landi MT; Little J; Newton-Bishop J; Sera F; Fargnoli MC; Raimondi S; ; ;
Lancet Child Adolesc Health; 2019 May; 3(5):332-342. PubMed ID: 30872112
[TBL] [Abstract][Full Text] [Related]
14. Inherited variation at MC1R and histological characteristics of primary melanoma.
Taylor NJ; Busam KJ; From L; Groben PA; Anton-Culver H; Cust AE; Begg CB; Dwyer T; Gallagher RP; Gruber SB; Orlow I; Rosso S; Thomas NE; Zanetti R; Rebbeck TR; Berwick M; Kanetsky PA
PLoS One; 2015; 10(3):e0119920. PubMed ID: 25790105
[TBL] [Abstract][Full Text] [Related]
15. Melanocortins and the melanocortin 1 receptor, moving translationally towards melanoma prevention.
Abdel-Malek ZA; Swope VB; Starner RJ; Koikov L; Cassidy P; Leachman S
Arch Biochem Biophys; 2014 Dec; 563():4-12. PubMed ID: 25017567
[TBL] [Abstract][Full Text] [Related]
16. Variants of the melanocortin-1 receptor: do they matter clinically?
Haddadeen C; Lai C; Cho SY; Healy E
Exp Dermatol; 2015 Jan; 24(1):5-9. PubMed ID: 25219681
[TBL] [Abstract][Full Text] [Related]
17. Lack of somatic alterations of MC1R in primary melanoma.
Kim RD; Curtin JA; Bastian BC
Pigment Cell Melanoma Res; 2008 Oct; 21(5):579-82. PubMed ID: 18761657
[TBL] [Abstract][Full Text] [Related]
18. Melanoma-associated melanocortin 1 receptor variants confer redox signaling-dependent protection against oxidative DNA damage.
Castejón-Griñán M; Cerdido S; Sánchez-Beltrán J; Lambertos A; Abrisqueta M; Herraiz C; Jiménez-Cervantes C; García-Borrón JC
Redox Biol; 2024 Jun; 72():103135. PubMed ID: 38565069
[TBL] [Abstract][Full Text] [Related]
19. Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study.
Fargnoli MC; Altobelli E; Keller G; Chimenti S; Höfler H; Peris K
Melanoma Res; 2006 Apr; 16(2):175-82. PubMed ID: 16567973
[TBL] [Abstract][Full Text] [Related]
20. Inherited variation at MC1R and ASIP and association with melanoma-specific survival.
Taylor NJ; Reiner AS; Begg CB; Cust AE; Busam KJ; Anton-Culver H; Dwyer T; From L; Gallagher RP; Gruber SB; Rosso S; White KA; Zanetti R; Orlow I; Thomas NE; Rebbeck TR; Berwick M; Kanetsky PA;
Int J Cancer; 2015 Jun; 136(11):2659-67. PubMed ID: 25382380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
